Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Selected Financial Data
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Statement

Vertex Pharmaceuticals Inc., selected items from income statement, long-term trends

US$ in thousands

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The analysis of the annual financial data reveals several notable trends in revenues, income from operations, and net income over the examined periods.

Revenues
The revenue figures demonstrate significant growth over the years. Starting from approximately 161 million US dollars in 2005, revenues generally increase with some fluctuations. A substantial jump occurs between 2010 and 2011, where revenues surge from around 143 million to over 1.4 billion US dollars. This upward momentum continues steadily, reaching over 11 billion US dollars by 2024. Despite minor drops in certain years, such as 2013 and 2014, the overall trend is strongly positive, indicating expanding business operations and market presence.
Income (loss) from operations
Operational income figures exhibit considerable volatility. The company experiences operational losses in the initial years from 2005 through 2010, with losses deepening to several hundreds of millions of US dollars, indicating challenges in controlling operating expenses or generating sufficient operating profit. A notable turnaround occurs in 2011, marked by a positive operational income of approximately 114 million US dollars, although this figure decreases sharply in the following years. After some oscillation, a strong operational profit growth phase emerges from 2016 onwards, peaking at about 2.85 billion US dollars in 2020. However, a decline is observed in 2023 and especially in 2024, where the figure drops to a negative 233 million, suggesting operational difficulties or increased costs impacting profitability.
Net income (loss)
Net income displays a pattern similar to that of income from operations, with initial losses persisting for several years up to 2010, indicating overall unprofitability during that phase. The net income turns positive in 2011 and shows significant improvement, particularly in 2017 and 2018 where the company posts profits exceeding 2 billion US dollars in 2018. Fluctuations are noted in the subsequent years; yet, profits remain robust through 2022 and 2023, though slightly lower than the peak years. The year 2024 reverses this trend sharply, with net income falling back into loss territory, with a deficit of over half a billion US dollars, revealing a notable deterioration in the company’s bottom-line performance.

Overall, the financial data illustrates a period of initial struggle characterized by sustained losses, followed by a phase of strong revenue growth and profitability beginning around 2011. The company achieves substantial operational and net income gains through to approximately 2022-2023. The final year analyzed shows a significant decline in both operational and net income, signaling potential challenges that warrant further investigation to understand underlying causes and implications.


Balance Sheet: Assets

Vertex Pharmaceuticals Inc., selected items from assets, long-term trends

US$ in thousands

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The analysis of the financial data over the presented period reveals several significant trends regarding the company's asset position.

Current Assets

Current assets exhibited an overall upward trend with some fluctuations. Beginning at approximately US$385 million in 2005, there was a notable increase in 2006 to around US$771 million. Despite a slight decline in 2007, the value substantially increased again, peaking intermittently over the years.

A marked growth phase is observable between 2014 and 2021, where current assets rose from around US$1.55 billion to a peak of over US$13.2 billion in 2022. However, a decline occurred thereafter, with current assets decreasing to approximately US$9.6 billion by the end of 2024.

This pattern suggests periods of asset accumulation, possibly linked to operational expansion or increased liquidity, followed by consolidation or asset utilization in the most recent years.

Total Assets

Total assets followed a broadly increasing trajectory over the period analyzed. Starting from about US$549 million in 2005, total assets experienced some volatility in early years but maintained an upward direction.

Significant acceleration is noted from 2013 onward, with total assets exceeding US$6.2 billion by 2017 and progressively rising to peak near US$22.7 billion in 2023. A slight decline appears at the latest date, with total assets recorded at approximately US$22.5 billion in 2024.

This cumulative growth reflects expansion in asset base, which may indicate increased investment in long-term assets, acquisitions, or reinvestments aligned with the company's strategic objectives.

Overall, both current and total assets show substantial growth over the nearly two decades observed, highlighting the company's asset base expansion. The fluctuations near the end of the period may warrant further analysis to ascertain causes such as changes in market conditions, strategic shifts, or financial restructuring.


Balance Sheet: Liabilities and Stockholders’ Equity

Vertex Pharmaceuticals Inc., selected items from liabilities and stockholders’ equity, long-term trends

US$ in thousands

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The financial data reveals distinct trends in the company’s liabilities and shareholders' equity over the twenty-year period ending December 31, 2024.

Current Liabilities
Current liabilities show significant variability with an overall rising trend. Starting at 100,243 thousand USD in 2005, current liabilities increased markedly to a peak of approximately 3,567,000 thousand USD by 2024. This growth indicates increased short-term obligations, with some fluctuations visible in the intervening years, particularly between 2014 and 2017 where a sharp rise can be observed.
Total Liabilities
Total liabilities have similarly escalated over the period. The figure rose from 309,822 thousand USD in 2005 to 6,123,600 thousand USD in 2024, indicating a substantial accumulation of both current and long-term obligations. Some notable changes include a spike from 330,182 thousand USD in 2007 to 741,605 thousand USD in 2008, and another steep increase after 2018 continuing through 2024.
Total Long-Term Obligations
The trend in long-term obligations is more fluctuating. It started at 180,097 thousand USD in 2005, declined considerably by 2007, but then surged to 683,201 thousand USD in 2012. After peaking at above 800,000 thousand USD in 2014-2016, it gradually declined to 118,000 thousand USD in 2024. This pattern suggests refinancing, repayments, or changes in long-term debt strategy over the years.
Shareholders’ Equity
Shareholders’ equity exhibits a strong upward trajectory, growing from 239,176 thousand USD in 2005 to an eventual peak of approximately 17,580,400 thousand USD in 2023 before a slight decrease in 2024. The increase is especially pronounced from 2012 onwards, reflecting expanded net assets and possibly retained earnings or new equity issuance. The dip in the final year may warrant attention regarding recent company performance or capital adjustments.

Overall, the data reflects a company that has significantly increased its financial scale. Both liabilities and equity have grown substantially, with liabilities showing more pronounced volatility and cyclical patterns, especially in long-term obligations. The strong growth in shareholders’ equity points to value generation, although the narrowing gap between equity and liabilities toward the latest years suggests a careful monitoring of the company’s leverage and capital structure is advisable.


Cash Flow Statement

Vertex Pharmaceuticals Inc., selected items from cash flow statement, long-term trends

US$ in thousands

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Operating Activities Cash Flow
The net cash flow from operating activities displayed significant volatility throughout the years. Initially, substantial negative cash flows were recorded from 2005 through 2010, reaching the most severe outflow in 2010 at approximately -635 million US dollars. From 2011 onwards, there was a marked improvement, shifting to positive net cash inflows, which peaked around 3.25 billion US dollars in 2020. Despite this strong performance in the early 2020s, the figures showed a sharp reversal in 2024, returning to a negative net cash outflow of nearly -493 million US dollars.
Investing Activities Cash Flow
The net cash flows from investing activities demonstrated a generally negative trend with considerable fluctuations over the entire period. Early years saw alternating signs, with a notable positive peak in 2007 at over 405 million US dollars, followed by consistent negative outflows, particularly large in 2009 and again from 2017 onward. The negative cash flow reached peak magnitude in 2024, amounting to approximately -3.77 billion US dollars, indicating substantial investment spends or asset acquisitions towards the end of the period.
Financing Activities Cash Flow
Financing activities exhibited wide swings between positive and negative net cash flows. From 2005 through 2006, the company experienced significant positive inflows, with values exceeding 365 million US dollars. Thereafter, the trend alternated frequently, with notable negative financing cash flows in several years, such as 2011 (-124 million US dollars), 2020 (-505 million US dollars), and a marked drop in 2021 reaching nearly -1.48 billion US dollars. The recent years reflected considerable financing outflows, with 2023 and 2024 showing net cash usage of approximately -562 million and -1.49 billion US dollars, respectively.

Per Share Data

Vertex Pharmaceuticals Inc., selected data per share, long-term trends

US$

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1, 2, 3 Data adjusted for splits and stock dividends.


The earnings per share (EPS) data over the period under review reveals distinct trends and fluctuations in the company's profitability.

Basic Earnings per Share (EPS)

From the end of 2005 through 2010, the basic EPS figures are consistently negative, indicating losses each year. The values start at -2.28 US$ per share in 2005 and reach a low of -3.77 US$ in 2010, reflecting increasing losses during this period.

In 2011, a notable improvement is observed as the basic EPS turns positive at 0.14 US$, representing a turnaround in profitability. However, this is followed by volatility from 2012 to 2014, where earnings again drop into negative territory, with values such as -0.50, -1.98, and -3.14 US$ per share, respectively.

Starting in 2015, the company shows a recovery and a mostly positive trend. The basic EPS improves significantly, becoming positive and increasing sharply to reach peaks in the years 2017 through 2023. The highest figure within this period is observed in 2023 at 14.05 US$ per share, illustrating robust profitability.

Contrarily, the most recent projection for 2024 shows a sharp decline with an estimated basic EPS of -2.08 US$, indicating a potential return to losses after several years of positive earnings.

Diluted Earnings per Share (EPS)

The diluted EPS closely follows the pattern of basic EPS throughout the observed years, which is typical as diluted EPS accounts for the potential dilution from convertible securities.

It remains negative from 2005 through 2010 with similar magnitudes as basic EPS. A positive EPS appears in 2011 at 0.14 US$, followed by a similar pattern of fluctuating negative values through 2014.

From 2015 onward, the diluted EPS also exhibits a strong positive trend, peaking at 13.89 US$ per share in 2023. The 2024 projection also shows a negative value of -2.08 US$, mirroring the basic EPS.

This close alignment between basic and diluted EPS values suggests limited dilution impact on the earnings available to shareholders during the periods analyzed.

Dividend per Share

There is no recorded dividend per share data throughout the entire period, indicating the company has not distributed dividends to shareholders during these years or such data is unavailable.

Overall, the company's earnings profile transitioned from persistent losses in the early years to sustained profitability from 2015 through 2023, marked by a peak in earnings in the last full reporting year. The projected figures for 2024, however, suggest a significant decline with an expected return to loss-making, which may warrant further investigation into underlying causes or external factors.